Eli Lilly Buys CrossBridge Bio

Eli Lilly is set to enhance its oncology pipeline through the acquisition of CrossBridge Bio. This strategic move aims to bolster the company's portfolio of cancer treatments by integrating CrossBridge's innovative research and development capabilities. The buyout is expected to accelerate the advancement of promising oncology drug candidates. Eli Lilly's acquisition underscores its commitment to expanding its presence in the oncology market and addressing unmet medical needs through targeted therapeutic development.